Skip to main content
Premium Trial:

Request an Annual Quote

Bruker s Revenues Soar 11 Percent, Loss Turns into Profit in Q2 of 2005

NEW YORK, Aug. 3 (GenomeWeb News) - Bruker BioSciences today reported increased revenues and a small net profit for the second quarter of 2005.


Revenues totaled $71.4 million for the quarter, up 11 percent over last year's $64.1 million during the same period. Of this, $37.4 million came from Bruker Daltonics, Bruker's mass spec business, up 7 percent from $34.9 million during the last year's second quarter. About 70 percent of the Daltonics revenues stem from mass spec systems for life sciences.


The company's research and development costs increased slightly, to $11 million, from $10.3 million during the second quarter of 2004.


Bruker reported a net income of $284,000, or $0 per share, up from a net loss of $4.4 million, or $.05 per share, for the same period last year.


As of June 30, Bruker had $92 million in cash and short-term investments.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.